Clinical genome editing to treat sickle cell disease - a brief update
Abstract: Sickle cell disease (SCD) is one of the most common hemoglobinopathies. Due to its high prevalence, with about 20 million affected individuals worldwide, the development of novel effective treatments is highly warranted. While transplantation of allogeneic hematopoietic stem cells (HSC) is the standard curative treatment approach, a variety of gene transfer and genome editing strategies have demonstrated their potential to provide a prospective cure for SCD patients. Several stratagems employing CRISPR-Cas nucleases or base editors aim at reactivation of γ-globin expression to replace the faulty β-globin chain. The fetal hemoglobin (HbF), consisting of two α-globin and two γ-globin chains, can compensate for defective adult hemoglobin (HbA) and reverse the sickling of hemoglobin-S (HbS). Both disruption of cis-regulatory elements that are involved in inhibiting γ-globin expression, such as BCL11A or LRF binding sites in the γ-globin gene promoters (HBG1/2), or the lineage-specific disruption of BCL11A to reduce its expression in human erythroblasts, have been demonstrated to reestablish HbF expression. Alternatively, the point mutation in the HBB gene has been corrected using homology-directed repair (HDR)-based methodologies. In general, genome editing has shown promising results not only in preclinical animal models but also in clinical trials, both in terms of efficacy and safety. This review provides a brief update on the recent clinical advances in the genome editing space to offer cure for SCD patients, discusses open questions with regard to off-target effects induced by the employed genome editors, and gives an outlook of forthcoming developments
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Frontiers in medicine. - 9 (2023) , 1065377, ISSN: 2296-858X
- Ereignis
-
Veröffentlichung
- (wo)
-
Freiburg
- (wer)
-
Universität
- (wann)
-
2023
- Urheber
- DOI
-
10.3389/fmed.2022.1065377
- URN
-
urn:nbn:de:bsz:25-freidok-2337330
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zarghamian, Parinaz
- Klermund, Julia
- Cathomen, Anton
- Universität
Entstanden
- 2023
Ähnliche Objekte (12)
Establishing a zinc finger nuclease platform for targeted genome editing in human cell lines, primary keratinocyte stem cells and cardiomyocytes in vivo
Entwicklung von gentechnologischen Strategien zur Überwindung der Bluthirnschranke am Modell des Morbus Gaucher Typ 2
Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi
CRISPR/Cas9 - einschneidende Revolution in der Gentechnik
Generation of safe CAR T cells to target B cell malignancies
Targeted gene transfer to enhance safety and efficacy of immunotherapy
Hijacking-DNA -Repair (HDR)-CRISPR promotes seamless gene editing in human primary cells
Genome editing of SNAI1 gene in rhabdomyosarcoma: a novel model for studies of its role
Targeted genome editing restores T cell differentiation in a humanized X-SCID pluripotent stem cell disease model
Editing the core region in HPFH deletions alters fetal and adult globin expression for treatment of [beta]-hemoglobinopathies
Gene therapy for STAT3-Associated Autosomal-Dominant Hyper-Ige-Syndrome (AD-HIES) using RNA-guided nucleases
Chimerization enables gene synthesis and lentiviral delivery of customizable TALE-based effectors
Establishing a zinc finger nuclease platform for targeted genome editing in human cell lines, primary keratinocyte stem cells and cardiomyocytes in vivo
Entwicklung von gentechnologischen Strategien zur Überwindung der Bluthirnschranke am Modell des Morbus Gaucher Typ 2
Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi
CRISPR/Cas9 - einschneidende Revolution in der Gentechnik
Generation of safe CAR T cells to target B cell malignancies
Targeted gene transfer to enhance safety and efficacy of immunotherapy
Hijacking-DNA -Repair (HDR)-CRISPR promotes seamless gene editing in human primary cells
Genome editing of SNAI1 gene in rhabdomyosarcoma: a novel model for studies of its role
Targeted genome editing restores T cell differentiation in a humanized X-SCID pluripotent stem cell disease model
Editing the core region in HPFH deletions alters fetal and adult globin expression for treatment of [beta]-hemoglobinopathies
Gene therapy for STAT3-Associated Autosomal-Dominant Hyper-Ige-Syndrome (AD-HIES) using RNA-guided nucleases
Chimerization enables gene synthesis and lentiviral delivery of customizable TALE-based effectors
Establishing a zinc finger nuclease platform for targeted genome editing in human cell lines, primary keratinocyte stem cells and cardiomyocytes in vivo
Entwicklung von gentechnologischen Strategien zur Überwindung der Bluthirnschranke am Modell des Morbus Gaucher Typ 2
Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi
CRISPR/Cas9 - einschneidende Revolution in der Gentechnik
Generation of safe CAR T cells to target B cell malignancies
Targeted gene transfer to enhance safety and efficacy of immunotherapy
Hijacking-DNA -Repair (HDR)-CRISPR promotes seamless gene editing in human primary cells
Genome editing of SNAI1 gene in rhabdomyosarcoma: a novel model for studies of its role
Targeted genome editing restores T cell differentiation in a humanized X-SCID pluripotent stem cell disease model
Editing the core region in HPFH deletions alters fetal and adult globin expression for treatment of [beta]-hemoglobinopathies
Gene therapy for STAT3-Associated Autosomal-Dominant Hyper-Ige-Syndrome (AD-HIES) using RNA-guided nucleases